These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 7625884)
21. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways. Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012 [TBL] [Abstract][Full Text] [Related]
22. Effects of 2-nicotinamidoethyl nitrate (nicorandil; SG-75) and its derivative on smooth muscle cells of the canine mesenteric artery. Inoue T; Kanmura Y; Fujisawa K; Itoh T; Kuriyama H J Pharmacol Exp Ther; 1984 Jun; 229(3):793-802. PubMed ID: 6233418 [TBL] [Abstract][Full Text] [Related]
24. Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Okada Y; Yokoyama T; Jinno Y; Kashiwabara T; Izawa T; Fukushima H; Ogawa N Eur J Pharmacol; 1993 Sep; 241(2-3):177-81. PubMed ID: 8243553 [TBL] [Abstract][Full Text] [Related]
25. Comparison of coronary dilating effects of Ki1769, a new K channel opener of the pyridinecarboximidamide type, and nifedipine in anesthetized dogs. Yokoyama T; Kaneta S; Miwa A; Tanaka Y; Izumi H; Izawa T; Ogawa N Arch Int Pharmacodyn Ther; 1994; 327(2):194-203. PubMed ID: 7979828 [TBL] [Abstract][Full Text] [Related]
26. Cardioprotective effects of KRN2391 and nicorandil on ischemic dysfunction in perfused rat heart. Ohta H; Jinno Y; Harada K; Ogawa N; Fukushima H; Nishikori K Eur J Pharmacol; 1991 Nov; 204(2):171-7. PubMed ID: 1839621 [TBL] [Abstract][Full Text] [Related]
27. Inotropic and coronary vasodilatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue. Müller-Ehmsen J; Brixius K; Hoischen S; Schwinger RH J Pharmacol Exp Ther; 1996 Dec; 279(3):1220-8. PubMed ID: 8968344 [TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship of a novel K+ channel opener, KRN4884, and related compounds in porcine coronary artery. Izumi H; Tanaka Y; Okada Y; Ogawa N; Izawa T Gen Pharmacol; 1996 Sep; 27(6):985-9. PubMed ID: 8909979 [TBL] [Abstract][Full Text] [Related]
29. K+ channel-opening action and KRN2391-induced reduction of Ca2+ sensitivity of arterial smooth muscle. Okada Y; Yanagisawa T; Yamagishi T; Taira N Arch Int Pharmacodyn Ther; 1993; 326():33-51. PubMed ID: 8185411 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular pharmacological characterization of novel 2,3-dimethyl-2-butylamine derivatives in rats. Chen YP; Qiu CR; Wang H Life Sci; 2004 Sep; 75(17):2131-42. PubMed ID: 15312756 [TBL] [Abstract][Full Text] [Related]
31. 2-Nicotinamidoethyl acetate (SG-209) is a potassium channel opener: structure activity relationship among nicorandil derivatives. Ishibashi T; Hamaguchi M; Imai S Naunyn Schmiedebergs Arch Pharmacol; 1991 Aug; 344(2):235-9. PubMed ID: 1658666 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the anti-vasoconstrictor effects of a novel vasodilator KRN2391, nicorandil and nifedipine on isolated porcine large coronary artery. Kasai H; Jinno Y; Kaneta S; Tanaka Y; Fukushima H; Izawa T; Ogawa N Arch Int Pharmacodyn Ther; 1993; 321():63-71. PubMed ID: 8323417 [TBL] [Abstract][Full Text] [Related]
33. Characteristics of Ki1769, a novel vasodilator, in isolated rat aorta. Kashiwabara T; Nakajima T; Kasai H; Nakajima S; Izawa T; Ogawa N Arch Int Pharmacodyn Ther; 1994; 327(2):175-83. PubMed ID: 7979826 [TBL] [Abstract][Full Text] [Related]
34. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo. Kamijo T; Iwai T; Haruta K; Takeda K Arch Int Pharmacodyn Ther; 1996; 331(3):273-84. PubMed ID: 9124999 [TBL] [Abstract][Full Text] [Related]
35. The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. Magnon M; Durand I; Cavero I J Pharmacol Exp Ther; 1994 Mar; 268(3):1411-8. PubMed ID: 7908056 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the potentiating effects of nicorandil and its denitrated metabolite (SG-86) on the adenosine-induced vasodepression in rats. Sakai K; Saito K Fundam Clin Pharmacol; 1998; 12(5):492-7. PubMed ID: 9794146 [TBL] [Abstract][Full Text] [Related]
37. KRN2391: dual action on rat pulmonary artery and no loss of potency in pulmonary hypertension. Wanstall JC; Gambino A; Thomas BJ Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):288-94. PubMed ID: 10779127 [TBL] [Abstract][Full Text] [Related]
38. Acute effects of increasing doses of nicorandil on renal function in man. Wolf DL; Jungbluth GL; Metzler CM; Froeschke MO; DeLoof MJ; Luderer JR Int J Clin Pharmacol Ther; 1994 May; 32(5):246-53. PubMed ID: 7921519 [TBL] [Abstract][Full Text] [Related]
39. Nicorandil opens a calcium-dependent potassium channel in smooth muscle cells of the rat portal vein. Kajioka S; Oike M; Kitamura K J Pharmacol Exp Ther; 1990 Sep; 254(3):905-13. PubMed ID: 2144320 [TBL] [Abstract][Full Text] [Related]
40. No development of tolerance to the hypotensive effect of KRN2391, a novel vasodilator containing a nitrate moiety. Kaneta S; Tanaka Y; Miwa A; Izawa T; Fukushima H; Ogawa N Arch Int Pharmacodyn Ther; 1993; 323():16-22. PubMed ID: 8250640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]